Ashraf Al Madhoun1,2, Fahad Alnaser3, Motasem Melhem1, Rasheeba Nizam1, Tala Al-Dabbous4, Fahd Al-Mulla1. 1. Genetics and Bioinformatics Department, Dasman Diabetes Institute, Dasman, 15462 Kuwait City, Kuwait. 2. Animal and Imaging Core Facility Department, Dasman Diabetes Institute, Dasman, 15462 Kuwait City, Kuwait. 3. Radiology Department, Ibn Sina Hospital, Ministry of Health, Kuwait City, Kuwait. 4. Bayt Abdullah Children's Hospice, NBK Children's Cancer Hospital, Al-Adan ICU, Kuwait City, Kuwait.
It is with great interest to read the comments of Dr. Josef Finsterer on our recent article, “Ketogenic diet attenuates cerebellar atrophy progression in a subject with a biallelic variant at the ATAD3A locus by Al Madhoun et al, 2019,” which has received a substantial article-level metrics and respond to the queries raised single nucleotide polymorphisms and deletion mutations within ATAD3 are lethal at embryonic stage or postnatally and the few survivors are living with low quality of life.1–3 Accordingly, ATAD3 genotyping enable prediction of genotype/phenotype relationship.Desai et al (2017) associated ATAD3 function with cholesterol homeostasis and maintenance of the mitochondrial genome stability.4 We thought that Ketogenic Diet (KD) may modulate mitochondrial biogenesis especially that it has proven efficacy in mitochondriopathies-mediated neurological disorders.5,6 Thus, it is not unrealistic to include KD treatment in a disease that is caused by ATAD3 gene mutations.The girl described in our paper is unique. She has been clinically evaluated extensively in Canada, but unfortunately, the family was not given a formal diagnosis. We diagnosed her with Harel-Yoon syndrome after discovering a novel pathogenic missense homozygous mutation in the ATAD3 gene (rs546711654 c.251C>T; p.Thr84Met). Globally, the variant allele frequency of rs546711654 is 0.0002 (https://www.ncbi.nlm.nih.gov/clinvar/variation/452865/). This information means that the disease is rare and therefore it is not possible to study other children harboring the same mutation.In response to KD, we never claimed an increase in the relative sagittal length of the cerebellum. But rather, an obvious slowing of her cerebellar atrophy. The KD was applied between the 2nd and 3rd MRI examination at the age of 4 and 5.5 years old. It has been reported that KD lowers the blood pH, increases ATP by shifting from glucose- to ketone-based metabolism.7 Although all body tissues are influenced by KD, the most prominent effect is on the nervous system activities.8,9 Accordingly, we do not exclude a positive effect on the muscle function.KD increases mitochondrial biogenesis.10,11 We agree that a real-effect of KD can only be assessed reliably in double-blind randomized clinical trials, but this is obviously not possible in very rare cases such as ours. However, the parents were surprised with the improved quality of life of the child.Science starts with an observation, which is then propagated through well-defined experimental procedures that address precise research questions. Our observation is a start and we look forward to learn how other children with cerebellar atrophy may benefit from our experience.As we clearly mentioned in the manuscript, the patient suffered from frank ataxia and intentional tremor secondary to her cerebellar atrophy. However, clinically she had clear pill-rolling resting tremor. In our experience, children with parkinsonism do not necessarily present with classical Parkinson’s disease symptoms. Neither DATScan test was performed nor L-DOPA was administered since compared to her other symptoms, particularly the severe osteoporosis, ataxia and intentional tremor, the parkinsonian tremor appeared minor. The functional neurological assessments included drawing, holding arms outstretched, gait and body posture and coordination.12 The patient did not suffer from epilepsy.No peripheral neuropathy was observed. Nerve conduct study revealed normal response at the peroneal and tibial terminal motor latency (1.95±0.24 ms), M-wave amplitudes were 3.6±0.2 mV and 8.5±1.1 mV, respectively, average duration 8.1±0.14 and the F-M wave latency was 20.7±0.6.The patient, as expected, in Harel-Yoon syndrome had bilateral cataract and no optic hypoplasia was observed in the subject. In Harel et al study, optic atrophy was detected in some patients, but not all1 other symptoms included congenital cataract, corneal cloudy and photophobia.1,2,13 No functional retinal tests were performed.It is important to note that the patient, during her long journey of diagnosis, has endured significant stress. Although we wish to perform many tests on her, we need to be diligent in our choices of tests. The family as mentioned above were disappointed with the lack of diagnosis after many years of laborious investigations, which culminated in more trauma, phycological and physical stress and were very rightly reluctant to undertake further tests. This is understandable. Moreover, mitochondria are present in every cell, while cerebellar atrophy appears to be the most likely presentation because of the high energy demand of neurons, one cannot exclude the possibility of pathologies in the muscle (myopathy), bone cells (osteoporosis), bone marrow, intestinal cells, etc. We are confident given our final diagnosis that the patients will have pathologies everywhere. Osteoporosis, bone fractures and osteomyelitis are now the major threat to the patient. When would one stop investigating?
Authors: Kristopher J Bough; Jonathon Wetherington; Bjørnar Hassel; Jean Francois Pare; Jeremy W Gawryluk; James G Greene; Renee Shaw; Yoland Smith; Jonathan D Geiger; Raymond J Dingledine Journal: Ann Neurol Date: 2006-08 Impact factor: 10.422
Authors: Tamar Harel; Wan Hee Yoon; Caterina Garone; Shen Gu; Zeynep Coban-Akdemir; Mohammad K Eldomery; Jennifer E Posey; Shalini N Jhangiani; Jill A Rosenfeld; Megan T Cho; Stephanie Fox; Marjorie Withers; Stephanie M Brooks; Theodore Chiang; Lita Duraine; Serkan Erdin; Bo Yuan; Yunru Shao; Elie Moussallem; Costanza Lamperti; Maria A Donati; Joshua D Smith; Heather M McLaughlin; Christine M Eng; Magdalena Walkiewicz; Fan Xia; Tommaso Pippucci; Pamela Magini; Marco Seri; Massimo Zeviani; Michio Hirano; Jill V Hunter; Myriam Srour; Stefano Zanigni; Richard Alan Lewis; Donna M Muzny; Timothy E Lotze; Eric Boerwinkle; Richard A Gibbs; Scott E Hickey; Brett H Graham; Yaping Yang; Daniela Buhas; Donna M Martin; Lorraine Potocki; Claudio Graziano; Hugo J Bellen; James R Lupski Journal: Am J Hum Genet Date: 2016-09-15 Impact factor: 11.025
Authors: Md Mahdi Hasan-Olive; Knut H Lauritzen; Mohammad Ali; Lene Juel Rasmussen; Jon Storm-Mathisen; Linda H Bergersen Journal: Neurochem Res Date: 2018-07-19 Impact factor: 3.996
Authors: J He; H M Cooper; A Reyes; M Di Re; H Sembongi; T R Litwin; J Gao; K C Neuman; I M Fearnley; A Spinazzola; J E Walker; I J Holt Journal: Nucleic Acids Res Date: 2012-03-26 Impact factor: 16.971
Authors: Radha Desai; Ann E Frazier; Romina Durigon; Harshil Patel; Aleck W Jones; Ilaria Dalla Rosa; Nicole J Lake; Alison G Compton; Hayley S Mountford; Elena J Tucker; Alice L R Mitchell; Deborah Jackson; Abdul Sesay; Miriam Di Re; Lambert P van den Heuvel; Derek Burke; David Francis; Sebastian Lunke; George McGillivray; Simone Mandelstam; Fanny Mochel; Boris Keren; Claude Jardel; Anne M Turner; P Ian Andrews; Jan Smeitink; Johannes N Spelbrink; Simon J Heales; Masakazu Kohda; Akira Ohtake; Kei Murayama; Yasushi Okazaki; Anne Lombès; Ian J Holt; David R Thorburn; Antonella Spinazzola Journal: Brain Date: 2017-06-01 Impact factor: 13.501
Authors: Helen M Cooper; Yang Yang; Emil Ylikallio; Rafil Khairullin; Rosa Woldegebriel; Kai-Lan Lin; Liliya Euro; Eino Palin; Alexander Wolf; Ras Trokovic; Pirjo Isohanni; Seppo Kaakkola; Mari Auranen; Tuula Lönnqvist; Sjoerd Wanrooij; Henna Tyynismaa Journal: Hum Mol Genet Date: 2017-04-15 Impact factor: 6.150